Brand
BD Pharmingen
Concentration
0.5 mg/ml
Isotype
Mouse IgG1, κ
Reactivity
Human (QC Testing) Mouse, Rat (Reported)
Application
Western blot (Routinely Tested)
ELISA, Immunohistochemistry-formalin (antigen retrieval required) (Reported)
Immunogen
Phosphorylated Human EGF Receptor Peptide
escription
Epidermal Growth Factor (EGF) elicits a variety of cellular responses that are initiated by EGF Receptor (EGFR) binding and activation of intrinsic tyrosine kinase activity. EGFR, also known as ErbB1 or HER1, is a member of the ErbB class of receptor protein tyrosine kinases. It has an extracellular ligand-binding domain, a single transmembrane region, and a cytoplasmic region containing a protein tyrosine kinase domain and a c-terminal regulatory domain with many phosphorylation sites. Following ligand binding, EGFR forms homodimers and heterodimers with ErbB2. Specific C-terminal tyrosine residues are then autophosphorylated and, in turn, bind to adaptor proteins, kinases, or protein tyrosine phosphatases. In addition, c-Src-dependent phosphorylations at other sites, such as tyrosine 845 (Y845) in the kinase domain, regulate the receptor's kinase activity. Inappropriate expression or mutations of EGFR and/or deregulation of its signaling pathways are associated with many types of cancer, making EGFR a promising target for cancer therapies.
The12A3monoclonal antibody recognizes the phosphorylated Y845 in the protein tyrosine kinase domain of human EGFR.